Analysis of Channels and Market Size of Japanese Peptide Products Entering China 1、 Global peptide market: a deterministic track of continuous high growth The global peptide drug market is expected to reach approximately $140.9 billion by 2025 and $294.6 billion by 2033, CAGR 8.73%。 The global peptide therapy drug market is expected to reach approximately 49.68 billion US dollars by 2026 and 70.2 billion US dollars by 2031, CAGR 7.16%。 In the Asia Pacific region, Japan is the largest single country market. The market size of non insulin peptide drugs in Japan is estimated to be between 6-8 billion US dollars in 2026, and is expected to reach 10-14 billion US dollars by 2035, CAGR 9-12%。 2、 Japan's exports to China: trade flow of high-value peptide raw materials The total export value of pharmaceutical products from Japan to China in 2025 is approximately 1.55 billion US dollars. In the field of peptide subdivision, Japan and Southeast Asia have become emerging hubs for peptide preparation reprocessing, with a 31% increase in peptide trade volume within the Asia Pacific region. At the same time, China's import value of peptide raw materials reached 3.25 billion US dollars in 2025, a year-on-year increase of 47.4%, becoming the core engine of raw material import growth. This import demand mainly comes from the procurement of raw materials for GLP-1 generic drug production by domestic pharmaceutical companies. 3、 Domestic demand: Over 50% of adults are overweight, GLP-1 channel outbreak The overweight/obesity rate among Chinese adults has reached 50.7% and is expected to rise to 65.3% by 2030. By 2025, the scale of China's pharmaceutical e-commerce market will reach 81 billion yuan, of which about 60% will come from prescription drugs, with GLP-1 drugs being an important driving force. Specifically on the product side: Simeglutide Injection will sell 1.626 billion yuan on e-commerce platforms in 2025, ranking second in pharmaceutical e-commerce sales. During the same period, the sales of Tilpotide Injection reached 757 million yuan, a year-on-year increase of nearly 2000 times. Liraglutide injection sold 600 million yuan, a year-on-year increase of 531.93%. The market size of peptide drugs in China is expected to reach 142.12 billion yuan by 2026. The peptide based weight loss drug market is currently experiencing explosive growth, with a global market size of approximately $72.02 billion for GLP-1 targeted peptide based weight loss drugs by 2025, expected to reach $157.51 billion by 2032, CAGR 12.0%。 4、 The channel forms of Japanese peptides entering the domestic market The channels through which Japanese peptide products enter the Chinese market exhibit multi-level characteristics: Cross border direct mail and purchasing channels: Food grade peptide products such as collagen peptides enter China through Japanese direct mail and cross-border e-commerce platforms. Japanese functional food raw material suppliers distribute raw materials such as bonito elastin peptide, red snapper collagen peptide, and collagen tripeptide to China through Chinese agents. Social media traffic: Discussions about purchasing GLP-1 drugs in Japan continue to be active on social media platforms, covering topics such as Japanese language services and tax-free purchases. The circulation of products such as the Japanese version of Tilpotide in private channels has become a public phenomenon. Individual brought into the country: Customs cases have shown that Japanese beauty injections continue to enter the country through methods such as personal restraint and luggage storage. B2B raw material trade: Japan and South Korea will import approximately 980 million US dollars of Chinese made amino acid and peptide intermediates in 2025, a year-on-year increase of 14%. Japan maintains a leading position in the field of functional peptide cosmetic raw materials and forms a two-way trade flow with China. 5、 Opportunity window for China's peptide industry GLP-1 generic drug window period: The core compound patent of semaglutide has expired in China, and domestic generic drugs have entered the review process. The industry predicts that by 2028, there will be 20 semaglutide generic drugs on the market in China. The promotion of generic drugs through channels, patient management, and out of hospital services is an open window. CDMO capacity transfer: The market size of peptide CDMO in China has grown from 1 billion yuan in 2018 to 3.6 billion yuan in 2023, CAGR 28.2%， It is expected to reach 13.4 billion yuan in 2028 and increase to 35.6 billion yuan in 2033. China has undertaken over 60% of global peptide CDMO orders. Consumer product upgrade: The demand for peptide applications in cosmetics and functional foods continues to grow, and by 2025, the market size of active peptide raw materials in this field will approach billions. The dual pursuit of efficacy and safety by consumers is driving the development of the industry chain towards high purity and stability. 6、 Core judgment The volume of Japanese peptide products entering China is continuously increasing. The demand side is driven by the outbreak of over 50% adult overweight rate and GLP-1 drugs, while the supply side is supported by Japan's mature peptide raw material industry and cross-border channels. This structural trend will not reverse due to short-term factors. For those who are interested in this track, what needs to be studied now is the compliance path of channels, the integration of supply chains, and how to complete the layout before the GLP-1 generic drug market window arrives.